Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes.

about

Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes.

Item

http://www.wikidata.org/entity/Q42314614

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Acute plasma amylase increase ...... nistration in Type 2 diabetes.

@en

Acute plasma amylase increase ...... nistration in Type 2 diabetes.

@nl

type

Item

label

Acute plasma amylase increase ...... nistration in Type 2 diabetes.

@en

Acute plasma amylase increase ...... nistration in Type 2 diabetes.

@nl

prefLabel

Acute plasma amylase increase ...... nistration in Type 2 diabetes.

@en

Acute plasma amylase increase ...... nistration in Type 2 diabetes.

@nl

P1476

Acute plasma amylase increase ...... nistration in Type 2 diabetes.

@en

P2093

D H van Raalte

http://www.w3.org/2001/XMLSchema#string

D L Cahen

http://www.w3.org/2001/XMLSchema#string

L Tonneijck

http://www.w3.org/2001/XMLSchema#string

M Diamant

http://www.w3.org/2001/XMLSchema#string

M H H Kramer

http://www.w3.org/2001/XMLSchema#string

P2860

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.

Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP.

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.

Daily rhythm of serum lipase and alpha-amylase activity in fed and fasted dogs.

P304

591-592

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DME.13160

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mark M Smits

Marcel H.A. Muskiet

P577

2016-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27278095

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5363237

http://www.w3.org/2001/XMLSchema#string